Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
Information source: University of Illinois
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Juvenile X-Linked Retinoschisis
Intervention: dorzolamide (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: University of Illinois Overall contact:
Gerald A Fishman, MD, Phone: 312.996.8939, Email: gerafish@uic.edu
Summary
Seven patients with X-linked retinoschisis were treated with dorzolamide and the response to
this treatment was monitored using OCT. These patients were also tested for the causative
gene mutation and the resultant mechanism of functional loss of retinoschisin. It was
observed that a response to dorzolamide may be seen irrespective of the mechanism that leads
to decrease in function of retinoschisin.
Clinical Details
Official title: Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Decrease in the size of cystic macular lesions as tested by OCT
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Presence of cystic lesions on OCT testing
Exclusion Criteria:
- Allergic reaction to sulpha containing compounds
- Intolerance to dorzolamide
Locations and Contacts
Gerald A Fishman, MD, Phone: 312.996.8939, Email: gerafish@uic.edu
University of Illinois Medical Center, Chicago, Illinois 60612, United States; Recruiting
Gerald A Fishman, MD, Phone: 312-996-8939, Email: gerafish@uic.edu
Additional Information
Starting date: October 2005
Last updated: July 14, 2008
|
